Telix has announced that the first patient has been dosed in a global Phase 2 study of its imaging agent TLX250-CDx (89Zr-DFO-girentuximab). …
First patient dosed in study of TLX250-CDx exploring indication expansion
June 19, 2023 Australian Biotech
Latest Video
New Stories
-
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News -
Australian company secures capital raise to advance amsulostat trials and strengthen pipeline
April 29, 2026 - - Latest News -
Australia urged to strengthen sunscreen literacy and label clarity
April 29, 2026 - -
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - - Latest News -
We need to say it again, just in case, that this advice is about ministerial choices and not conditions
April 29, 2026 - - Latest News -
Families welcome cancer drug progress but remain cautious over timely access
April 28, 2026 - - Latest News